High-Content Screening for Adverse Cytologic Effects
Peter OBrien, Clinical Pathologist, University College Dublin
The first, highly-effective, high-content-screening (HCS) for adverse
cytologic effect was reported a decase ago (Arch Toxicol 2006, 80, 580).
Success was attributed to simultaneous measurement of multiple
“cytobiomarkers”, use of human cells that can metabolise drugs, 72 h
exposure for slow toxicants, exposure to wide-ranging concentrations,
and normalizing toxic to efficacious concentration. Many HCS studies
now support this approach as necessary in predictive toxicology, as does
review of literature since the ?rst cytotoxicity assay was reported 100
years ago. A subset of the original toxicants was reanalyzed using the
original HCS confirming high sensitivity and speci?city across
locations, technologies, sta?, laboratories, and time. A protocol is
demonstrated for operational validation of the HCS within labs to
document pro?ciency and quality management.
|
|